MX2018008903A - COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. - Google Patents

COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.

Info

Publication number
MX2018008903A
MX2018008903A MX2018008903A MX2018008903A MX2018008903A MX 2018008903 A MX2018008903 A MX 2018008903A MX 2018008903 A MX2018008903 A MX 2018008903A MX 2018008903 A MX2018008903 A MX 2018008903A MX 2018008903 A MX2018008903 A MX 2018008903A
Authority
MX
Mexico
Prior art keywords
hmb
lipophagy
methods
methylbutyrate
hydroxy
Prior art date
Application number
MX2018008903A
Other languages
English (en)
Inventor
Rathmacher John
Abumrad Naji
Baier Shawn
Original Assignee
Metabolic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Tech Inc filed Critical Metabolic Tech Inc
Publication of MX2018008903A publication Critical patent/MX2018008903A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención proporciona una composición que comprende HMB. También se describen métodos para administrar HMB a un animal. El HMB se administra para modular la autofagia y lipofagia. El HMB también se administra para tratar, prevenir, inhibir, retardar o reducir condiciones o enfermedades mediadas por autofagia.
MX2018008903A 2016-01-21 2017-01-20 COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. MX2018008903A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662281561P 2016-01-21 2016-01-21
PCT/US2017/014328 WO2017127675A1 (en) 2016-01-21 2017-01-20 COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY

Publications (1)

Publication Number Publication Date
MX2018008903A true MX2018008903A (es) 2019-02-21

Family

ID=59360054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008903A MX2018008903A (es) 2016-01-21 2017-01-20 COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.

Country Status (9)

Country Link
US (1) US10213399B2 (es)
EP (2) EP3405262A4 (es)
JP (3) JP2019506393A (es)
CN (1) CN109641135A (es)
AU (2) AU2017210335A1 (es)
BR (2) BR112018014920A2 (es)
CA (1) CA3011981C (es)
MX (1) MX2018008903A (es)
WO (1) WO2017127675A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11406609B2 (en) * 2016-01-21 2022-08-09 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy
WO2018012769A1 (ko) * 2016-07-12 2018-01-18 연세대학교 산학협력단 자가포식 향상물질 및 그 용도
CN109549953A (zh) * 2017-09-27 2019-04-02 中国科学技术大学 调控tfeb以减弱保护性自噬促进纳米银抗肿瘤治疗的方法
BR112021022752A2 (pt) * 2019-06-20 2022-03-22 Nestle Sa Composições e métodos para potencializar o efeito músculo-esquelético de um ou mais aminoácidos anabólicos
CN110724203B (zh) * 2019-11-08 2021-04-30 中国人民解放军第四军医大学 一种促进tfeb核转位的短肽及基于其的线性短肽和其减轻脑缺血损伤的应用
CN111227243A (zh) * 2020-02-28 2020-06-05 昆明医科大学第一附属医院 一种具有特殊医学用途配方的食品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028440A (en) 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
NZ256300A (en) 1992-09-16 1997-06-24 Univ Iowa State Res Found Inc Administration of beta-hydroxy-beta-methyl butyric acid, or its convertible forms, to lower cholesterol levels
US5348979A (en) 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20120053240A1 (en) 2009-12-18 2012-03-01 Metabolic Technologies, Inc. Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)
MX2014000419A (es) * 2011-07-15 2014-09-22 Nusirt Sciences Inc Composicones y metodos para modular trayectorias metabolicas.
EP2647374A1 (en) * 2012-04-04 2013-10-09 Abbott Laboratories, Inc. Nutritional compositions including beta-hydroxy-beta-methylbutyrate for regulating transcription factors
EP3052133A2 (en) * 2013-10-03 2016-08-10 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
CA2944004C (en) * 2014-03-27 2023-08-15 Roland W. Winterfield Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
FI3302704T3 (fi) * 2015-06-01 2023-02-28 Metabolic Tech Inc Beta-hydroksi-beeta-metylibutyraatin (hmb) koostumuksia ja käyttömenetelmiä rasvamassan vähentämiseksi

Also Published As

Publication number Publication date
BR112018014920A2 (pt) 2018-12-18
US20170209397A1 (en) 2017-07-27
CA3011981A1 (en) 2017-07-27
EP4049723A1 (en) 2022-08-31
AU2017210335A1 (en) 2018-08-02
WO2017127675A1 (en) 2017-07-27
EP3405262A4 (en) 2019-08-28
BR122023026038A2 (pt) 2024-01-16
JP2022088611A (ja) 2022-06-14
AU2022246406A1 (en) 2022-11-03
JP2019506393A (ja) 2019-03-07
JP2024010082A (ja) 2024-01-23
CA3011981C (en) 2024-01-16
CN109641135A (zh) 2019-04-16
EP3405262A1 (en) 2018-11-28
US10213399B2 (en) 2019-02-26

Similar Documents

Publication Publication Date Title
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
EA201790992A1 (ru) Иммунорегуляторные агенты
PH12015502028A1 (en) Ido inhibitors
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
CR20190531A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2018011788A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MX2019013893A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
PH12020552060A1 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
PH12016502352A1 (en) Pharmaceutical composition
NZ757081A (en) Somatostatin modulators and uses thereof
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX2018007074A (es) Moduladores de canales de kv3 para tratar dolor.
TW201613578A (en) Pharmaceutical combinations
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.